Department of Radiation Medicine and Applied Sciences, University of California San Diego, La Jolla.
Department of Radiation Oncology, Stanford University, Stanford, CA.
Am J Clin Oncol. 2022 Feb 1;45(2):74-80. doi: 10.1097/COC.0000000000000888.
While opioids represent a cornerstone of cancer pain management, the timing and patterns of opioid use in the cancer population have not been well studied. This study sought to explore longitudinal trends in opioid use among Medicare beneficiaries with nonmetastatic cancer.
Within a cohort of 16,072 Medicare beneficiaries ≥66 years old diagnosed with nonmetastatic cancer between 2007 and 2013, we determined the likelihood of receiving a short-term (0 to 6 mo postdiagnosis), intermediate-term (6 to 12 mo postdiagnosis), long-term (1 to 2 y postdiagnosis), and high-risk (morphine equivalent dose ≥90 mg/day) opioid prescription after cancer diagnosis. Multivariable logistic regression models were used to identify patient and cancer risk factors associated with these opioid use endpoints.
During the study period, 74.6% of patients received an opioid prescription, while only 2.66% of patients received a high-risk prescription. Factors associated with use varied somewhat between short-term, intermediate-term, and long-term use, though in general, patients at higher risk of receiving an opioid prescription after their cancer diagnosis were younger, had higher stage disease, lived in regions of higher poverty, and had a history of prior opioid use. Prescriptions for high-risk opioids were associated with individuals living in regions with lower poverty.
Temporal trends in opioid use in cancer patients depend on patient, demographic, and tumor characteristics. Overall, understanding these correlations may help physicians better identify patient-specific risks of opioid use and could help better inform future evidence-based, cancer-specific opioid prescription guidelines.
阿片类药物是癌症疼痛管理的基石,但癌症患者使用阿片类药物的时间和模式尚未得到充分研究。本研究旨在探讨医疗保险受益人群中患有非转移性癌症患者的阿片类药物使用的纵向趋势。
在一个由 16072 名 66 岁及以上、2007 年至 2013 年间被诊断为非转移性癌症的医疗保险受益人群组成的队列中,我们确定了在癌症诊断后接受短期(0 至 6 个月)、中期(6 至 12 个月)、长期(1 至 2 年)和高危(吗啡等效剂量≥90mg/天)阿片类药物处方的可能性。多变量逻辑回归模型用于确定与这些阿片类药物使用终点相关的患者和癌症风险因素。
在研究期间,74.6%的患者接受了阿片类药物处方,而只有 2.66%的患者接受了高危处方。短期、中期和长期使用之间的相关因素略有不同,但总体而言,癌症诊断后接受阿片类药物处方风险较高的患者年龄较小,疾病分期较高,生活在贫困程度较高的地区,并有阿片类药物使用史。高危阿片类药物处方与生活在贫困程度较低地区的个体有关。
癌症患者阿片类药物使用的时间趋势取决于患者、人口统计学和肿瘤特征。总的来说,了解这些相关性可以帮助医生更好地识别患者特定的阿片类药物使用风险,并有助于更好地为未来基于证据的、针对癌症的阿片类药物处方指南提供信息。